Brought to you by 
Chiesi plans to take complete ownership of Cornerstone; finalized
23 Sep 2020
Executive Summary
Italian drug company Chiesi Farmaceutici SPA has proposed to acquire the remaining 40% of publicly traded spec pharma Cornerstone Therapeutics Inc. that it doesn’t already own for $6.40-6.70 in cash per share (a 21% premium on the midpoint), valuing the deal as high as $70.9mm. Cornerstone has put together a five-member special committee to review the offer.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chiesi plans to take complete ownership of Cornerstone; finalized
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice